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Comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) 
have become invaluable tools for the diagnosis and identification of numerous 
chromosomal aberrations either in haematological malignancies or solid tumors. CGH 
is a modified in situ hybridization technique that allows detection and mapping of DNA 
sequence copy differences between two genomes in a single experiment whereas FISH 
is a quantitative analysis of specific chromosomes and genes. In this study, both 
techniques were used in three gliomas cell lines; A172 (glioblastoma), U87 MG 
(astrocytoma grade 111) and T98G (glioblastoma multiforme) to investigate the genomic 
imbalance and to detect cancer-related genes before and after treatment with a new 
synthetic cadmium compound. ~is[~-meth~l-@-~-(2-furylmeth~lketone) 
dithiocarbazato] cadmium@) (SMDB-Cd) was synthesized at the Chemistry 
Department, Faculty of Science, Universiti Putra Malaysia and has shown to have 
potential as an anticancer agent. The EC50 values for SMDB-Cd on A172, U87MG, 
T98G and HCN-2 were at 0.7, 0.3, 0.4 and 1.5 pglml respectively, while tamoxifen 
which is commonly used to treat brain cancer were at 7.0, 5.0,4.0 and 6.0 pg/ml. CGH 
data indicated that these three cell lines have various DNA copy number changes; the 
most frequent DNA gains found were at 7p and 13q, and losses of chromosome 9p, 17p 
and 19q indicate that these regions contain candidate tumor suppressor genes involved 
in gliomas. Upon treatment with SMDB-Cd at those EC50 concentrations, U87 MG was 
shown to be more sensitive to SMDB-Cd compared to A172 and T98G. Chromosome 
7p did not show any changes in DNA amplification or deletetion. Involvement of one of 
the important tumor suppressor genes in many human cancers, p53, which is mapped to 
the short arm of chromosome 17, was then examined. The amplification status of this 
region was evaluated by using FISH through the locus specific p53 (17~13.1) probe. 
About 60% of cells were detected to have deletion on one or both copies of the p53 
gene in A172 and U87MG. However, two copies of the p53 gene were detected in 
T98G, which means there is no deletion of p53. These results agree with the previous 
study on the association of p53 mutation with different subtypes of gliomas. After 
treatment with SMDB-Cd, p53 level was observed to be amplified in T98G. Increasing 
of p53 level may have been induced by the action of SMDB-Cd on the cells that inhibit 
cell growth and lead to cell damage. Thus, the combined use of CGH and FISH 
provided an efficient method for resolving the origin of aberrant chromosomal material 
unidentified by conventional cytogenetic analysis. CGH was observed to be a powerful 
tool in assisting the screening of amplification and deletion regions in glioma cell lines 
upon treatment with SMDB-Cd. Use of FISH to confirm the involvement of the p53 
gene further enhances the validity of the technique. 
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Perbandingan penghibridan genom (CGH) dan penghibridan in situ fluoresen (FISH) 
telah menjadi teknik yang sangat bernilai dalam diagnosis dan pengenalpastian pelbagai 
kesilapan kromosom sama ada di dalam pertumbuhan kanser darah atau kanser solid. 
CGH adalah teknik penghibridan in situ yang telah diubah suai untuk mengesan dan 
merajahkan perbezaan rangkaian DNA di antara dua gen dalam satu kajian manakala 
FISH adalah teknik yang berasaskan analisa kuatitatif terhadap kromosom dan gen yang 
khusus. Di dalam kajian ini, kedua-dua teknik di gunakan keatas tiga jenis sel glioma; 
A172 (glioblastoma), U87MG (astrocytoma gred 111) dan T98G (glioblastoma 
multiforme) untuk menyelidik ketidakseimbangan genom dan mengesan gen-gen yang 
berkait rapat dengan pembentukan kanser glioma sebelum dan selepas dirawat dengan 
sintebk kompoun kadmium. ~is[~-meth~l-~-~-(2-furylmeth~lketone) dithiocarbazato] 
cadrmum(I1) (SMDB-Cd) yang disintesiskan di jabatan kimia, fakuli sains dan alam 
sekitar, Universiti Putra Malaysia telah menunjukkan potensi sebagai anti kanser. Nilai 
EC50 untuk SMDB-Cd pada A172, U87MG, T98G dan HCN-2 adalah 0.7,0.3,0.4 dan 
1.5 pg/ml dibandingkan dengan tamoxifen yang selalu digunakan dalam merawat 
kanser otak iaitu 7.0, 5.0, 4.0 dan 6.0 pglml. CGH telah mengenal pasti pelbagai 
perubahan salinan DNA didalam ketiga - tiga sel tersebut; yang paling kerap dilihat 
adalah pertambahan DNA pada 7p dan 13q manakala kehilangan DNA adalah pada 
kromosom 9p, 17p dm 19q di mana bahagian - bahagian tersebut mengandungi gen 
supresor tumor yang terlibat dalam gliomas. Selepas dirawat dengan SMDB-Cd pada 
kepekatan ECs0:, U87MG telah menunjukkan tindak balas yang lebih sensitive terhadap 
kompoun tersebut berbanding dengan A172 dan T98G. Kromosom 7p tidak 
menunjukkan sebarang penambahan atau kehilangan DNA. Penglibatan satu gen 
supresor kanser, p53 yang terletak pada bahagian pendek kromosom 17 telahdiuji. 
Status peningkatan bahagian ini telah dinilai dengan menggunakan FISH melalui probe 
khusus untuk loci p53 (17~13.1). Hampir 60% dari sel - sel A172 dan U87MG 
menunjukkan tiada salinan atau satu salinan gen p53 sahaja yang dilihat. Walau 
bagaimanapun, terdapat dua salinan gen p53 yang dikenal pasti didalam T98G 
bermakna tidak ada kehilangan gen p53. Keputusan ini bersetuju dengan kajian 
terdahulu mengenai hubungan gen p53 dengan jenis - jenis gliomas. Selepas diben 
SMDB-Cd, terdapat peningkatan paras p53 di dalam T98G. Peningkatan paras p53 ini 
di dalam sel - sel yang dirawat mencadangkan kemungkinan tindakan kompoun sintetik 
tersebut keatas sel yang menghalang pertumbuhan sel dan menyebabkan kemusnahan 
sel. Maka, kombinasi CGH dan FISH memberikan kaedah yang berkesan dalam 
meyelesaikan permulaan kepelbagaian kromosom yang tidak dapat dikenal pasti 
melalui analisis sitogenebk konventional. Keputusan ini menunjukkan CGH adalah satu 
teknik yang boleh digunakan dalam penyaringan peningkatan dan kehilangan bahagian- 
bahagian yang terlibat dalam sel-sel glioma sama ada sebelum atau selepas dirawat 
dengan SMDB-Cd. FISH sebagai pengesahan teknik kepada gen p53 tersebut yang 
meningkatkan lagi kesahihan kaedah tersebut. 
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CHAPTER 1 
INTRODUCTION 
Currently, molecular cytogenetic techniques that are based on fluorescence in situ 
hybridization (FISH), have become invaluable tools for the diagnosis and identification 
of the numerous chromosomal aberrations which are associated with neoplastic disease, 
including both haematological malignancies and solid tumors. This is because the 
etiologies of these genetic diseases involve a complex interplay of numerous acquired 
genetic abnormalities, including amplification of oncogenes, deletion of tumor 
suppressor genes, gene rearrangements and loss or gain of function mutations (McNeil 
et al., 2000). 
Molecular cytogenetic techniques focus on specific chromosomes, chromosome regions 
and unique DNA sequences or genes as compared to standard cytogenetic techniques. 
With these techniques, some chromosomal abnormalities in nondividing cells can be 
detected with interphase nuclei instead of using standard cytogenetics which require 
actively dividing cells with metaphase nuclei. In other words, the molecular cytogenetic 
techniques can be used as a complementary technique which will expand the 
capabilities for making more accurate and refined cytogenetic diagnosis either for 
constitutional abnormalities or acquired chromosomal changes in cancer cells (Table 1) 
(Rautenstrauss and Liehr, 2002). 
Table 1: Milestones in karyotyping and molecular cytogenetics (adapted from 
Rautenstrauss and Liehr, 2002) 
Early findings 
Pre - banding 
era 
Banding era 
Several authors in the 
19& century 
1 882 Flemming 
1 8 83 Roux 
1944 Avery et al. 
1952 Hsu 
1953 Watson 
1956 Tjio & Levan 
1958 Ford, Jacobs & 
Lajtha 
1 959 Lejeune et al. 
1960 Ford et al. 
1960 Edwards et al; 
Patau et a1 
1960 Nowell & 
Hungerford 
1968 Carpesson et al. 
1970 Chaudhuri et 
I . ,  Caspersson et 
cz 1. 
1970 Smith & 
Wilcox 
Kelly & Smith 
1971 
Cell theory 
Mendel's law of inheritance 
First identification of miotic figures 
Behavior of chromosomes in a dividing cell 
DNA - transforming factor 
Hypotonic treatment of cells 
DNA double helix and genetic implications 
46 chromosomes 
First chromosome analysis in leukemia 
First chromosomal diseases: 
- (Down's syndrome) trisomy of one of the 
smallest chromosomes 
- Turner's syndrome (monosomy X) 
Denver Conference 23 human chromosome 
pairs divided by morphology into 7 groups 
(A - GI 
- Trisomy for a D - group chromosome 
- Trisomy for an E - group chromosme 
First identification of chromosomal disorder 
related to leukaemia 
Quinacrine mustard banding 
G and Q banding refined 
450 - 550 bandslmetaphase 
Birth of molecular genetics specific 
restriction endonucleases 
Paris Conference - first cytogenetic 
nomenclature of all 23 chromosome   airs 
FISH era 
1 973 Cohen et al. 
1976 Yunis 
1981 
198 1 Harper & 
Saunders; 
Malcolm et al.; 
Gerhard et al. 
198 1 Langer et al. 
1985 
1986 Saiki et a1 
1986 Pinkel et al. 
1986 Deaven et al. 
1988 Pinkel et al. 
Cremer et al. 
1988 Lichter et al. 
1990 Nederlof et al. 
1992 Telenius et al. 
1992 Kallioniemi et 
al. 
1995 Mitelman 
1996 Schrock et al. 
Speicher et al. 
\ 
1998 Choudoba et al. 
First report on cloning DNA using plasmids 
as vectors 
High resolution chromosome banding 
(up to 2000 bandslprophase) 
Localization of single copy genes by insitu 
hybridization 
Biotin - labeled nucleotides 
International System for Human 
Cytogenetic Nomenclature (ISCN 1985) 
PCR technology 
Fluorescence hybridization 
Chromosome specific DNA libraries 
Fluorescence in situ hybridization with 
human chromosome specific libraries 
CISS hybridization 
Multi - color FISH 
Supplement to ISCN now including cancer 
cytogenetics 
DOP - PCR 
CGH - analysis 
Supplement to ISCN now including FISH 
nomenclature 
24 - color karyotyping spectral karyotyping 
multicolor karyotyping 
High resolution bar coding 
Improvement of the cytogenetic techniques from a conventional method such as G- 
banding to modem cytogenetic techniques such as fluorescence in situ hybridization 
(FISH) has enabled the finding of abnormalities in chromosome number and structure 
more quickly. FISH probes have been designed to detect specific regions of DNA and 
thus to elucidate abnormalities even at the level of the gene which cannot be detected by 
conventional techniques. Some of the advantages of FISH include the confirmation of 
chromosome breakpoints, an assessment of specific nucleic acid sequences and the 
ability to detect such sequences in non-dividing cells (i.e. interphase nuclei). Although 
FISH is an extremely useful technique, until recently only a few target sequences could 
be visualized simultaneously (McNeil et al., 2000). 
By contrast, comparative genomic hybridization (CGH) is widely used as a powerful 
method for detection and identification of chromosomal imbalances in a wide range of 
tumor samples (Kallioniemi et al., 1992). The technique gives an overview of gains and 
losses of whole chromosomes or regions as well as amplifications and deletions of 
smaller segments. Identification of the chromosomal gains and losses is carried out by 
using differentially labeled tumor DNA and normal DNA. On visualizing the two 
different fluorochromes, differences in the intensity of fluorescence along the 
chromosome correspond to the loss or gain of genetic material in the tumor sample 
(McNeil et al., 2000). Currently, the amplification of single genes have been 
documented, while deletions are detectable only on a larger scale (band size) (Barch et 
al., 1997). The technique of CGH, which has also been referred to as copy number of 
karyotyping may target a locus for molecular analysis or indicate pathways leading to 
tumor progression, recurrence and metastasis (Barch et al., 1997). 
In solid tumors, classical cytogenetic preparation has been less successful because of 
the difficulty of obtaining high quality representative metaphase chromosome 
preparations and to analyze the chromosomes that may not be representative of the 
tumor. Sometimes, the preparation of chromosome may have contamination of the 
specimen with normal tissue. The potential for multiple abnormal clones which contain 
high level of chromosomal rearrangements makes karyotyping analysis complicated. 
The complex nature of those rearrangements makes them indecipherable by banding 
techniques (Barch et al., 1997). Therefore, the advent of molecular cytogenetic 
techniques in the late 1960s, which is the visualization of loci using the dynamic 
biochemical technique of in situ hybridization, has helped to detect chromosomal 
aberrations. In the case of solid tumors and leukaemia, obtaining of the metaphase 
chromosome spreads in conventional technique is difficult therefore in molecular 
cytogenetic, preparation of metaphase chromosome spreads from the sample is 
unnecessary that will help to analyze the chromosome in those diseases. 
Research in cancer biology unequivocally shows that cancer tumors have a wide variety 
of aberrations in the organization and content of their genomes as compared with the 
genomes of normal cells. This genomic instability which is defined as the dynamic 
process of genomic changes in a tumor cell over time is a general feature of cancer 
cells. It displays an elevation of mutation rates during tumor progression that results in 
